Download PDF

1. Company Snapshot

1.a. Company Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally.It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors.


It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc.for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema.The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Show Full description

1.b. Last Insights on ALIM

Negative drivers behind Alimera Sciences' recent performance include the pending acquisition by ANI Pharmaceuticals, which may have led to increased uncertainty and volatility in the stock. The acquisition was initiated on September 16, 2024, and completed on the same day, which may have caused short-term disruption to the company's operations and investor sentiment. Additionally, the recent trend in earnings estimate revisions may not translate into further price increase in the near term, potentially weighing on the stock's performance.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

Sep -16

Source: globenewswire.com

Card image cap

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

Sep -16

Source: globenewswire.com

Card image cap

Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?

Sep -12

Source: zacks.com

Card image cap

ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences

Sep -10

Source: globenewswire.com

Card image cap

Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates

Aug -06

Source: zacks.com

Card image cap

Alimera Sciences Reports Second Quarter 2024 Results

Aug -06

Source: globenewswire.com

Card image cap

ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.

Jul -27

Source: globenewswire.com

Card image cap

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Bally's Corp. - BALY

Jul -26

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Ophthalmic Retinal Pharmaceuticals

Expected Growth: 8.5%

Alimera Sciences' Ophthalmic Retinal Pharmaceuticals segment growth of 8.5% is driven by increasing prevalence of diabetic retinopathy, rising demand for ILUVIEN (fluocinolone acetonide intravitreal implant) in diabetic macular edema treatment, and expanding geographic presence in Europe and Asia.

7. Detailed Products

ILUVIEN

A fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME)

ILUVIEN LICENSED

A fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular edema (DME)

8. Alimera Sciences, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Alimera Sciences, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the pharmaceutical industry.

Bargaining Power Of Customers

Alimera Sciences, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Alimera Sciences, Inc. relies on a few key suppliers for raw materials and manufacturing services. While the company has some bargaining power due to its size, the suppliers also have some leverage due to the specialized nature of their products.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs. This makes it difficult for new entrants to enter the market and compete with established players like Alimera Sciences, Inc.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players competing for market share. Alimera Sciences, Inc. faces intense competition from other companies developing similar products, which can lead to pricing pressure and reduced market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 58.59%
Debt Cost 9.93%
Equity Weight 41.41%
Equity Cost 9.93%
WACC 9.93%
Leverage 141.47%

11. Quality Control: Alimera Sciences, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Supernus Pharmaceuticals

A-Score: 5.3/10

Value: 2.6

Growth: 6.0

Quality: 7.6

Yield: 0.0

Momentum: 9.0

Volatility: 6.7

1-Year Total Return ->

View Full Report
Stock-Card
Amphastar Pharmaceuticals

A-Score: 4.8/10

Value: 7.1

Growth: 8.8

Quality: 8.0

Yield: 0.0

Momentum: 0.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Journey Medical

A-Score: 4.0/10

Value: 6.6

Growth: 3.3

Quality: 4.3

Yield: 0.0

Momentum: 8.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
PetIQ

A-Score: 3.5/10

Value: 3.6

Growth: 7.8

Quality: 3.1

Yield: 0.0

Momentum: 5.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Aytu BioPharma

A-Score: 3.4/10

Value: 9.6

Growth: 4.8

Quality: 4.4

Yield: 0.0

Momentum: 1.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Alimera Sciences

A-Score: 2.5/10

Value: 2.4

Growth: 4.7

Quality: 2.3

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

5.54$

Current Price

5.54$

Potential

-0.00%

Expected Cash-Flows